Anlon Healthcare’s ₹121 crore IPO was 1.69x overall subscribed on Day 1 with a robust retail bid, whereas institutional interest and GMP patterns remained subdued.

Anlon Healthcare IPO Day 1

India’s primary market witnessed fresh activity when Anlon Healthcare got off with a ₹121 crore IPO on August 26, 2025, drawing good attention from retail investors on its opening day. The overall subscription touched 1.69 times while the grey market premium (GMP) stayed flat at ₹5, indicating only moderate listing expectations despite a retail frenzy.

Day 1 Subscription Snapshot

At the end of the first day, the IPO showed 1.69x overall subscription. Retail investors took the initiative with their quota being oversubscribed 8.99 times, whereas institutional demand was rather weak (QIBs at 0.91x and NIIs at 0.71x).

The subdued GMP of ₹5, or a 5.49% premium, outlines a cautious approach towards short-term listing gains. Analysts say that the call subscription momentum will become obvious as they reach the final day, upon which institutional investors will make their moves.

Anlon Healthcare is the manufacturer of pharmaceutical intermediates and active ingredients (APIs) needed for drug production. The company does not sell finished medicines but instead provides the necessary building blocks for tablets, capsules, syrups, skincare products, nutraceuticals, and veterinary health solutions.

As of March 31, 2025, Anlon had 65 commercial products, 28 at the pilot stage, and 49 under development. Besides that, it also does custom chemical manufacturing and helps pharma companies with the regulatory filings for their global exports.

Use of IPO Proceeds

The company will direct the money to capacity expansion, debt repayment, and working capital:

• ₹30.72 crore – Expansion of the plant with a capacity of 700 MTPA (current 400 MTPA).
• ₹5 crore – Debt repayment.
• ₹43.15 crore – Working capital for the purchase of raw materials and for the daily activities of the company.
• Balance – For general corporate purposes.

Financial Strengths

• Profits skyrocketed almost 4x in two years: from ₹5.8 crore (FY23) to ₹20.5 crore (FY25).
• The debt-to-equity ratio was reduced dramatically from 9x to 0.73x.
• Customer satisfaction with 33 audits in FY25 and no cancellations of orders.
• DMF certifications in Brazil, China, and Japan have removed barriers to global markets.

Key Risks

• The sales dropped from ₹113 crore in FY24 to ₹67 crore, reflecting revenue instability.
• The top 10 customers (77.7% of the revenue) are the major source of the company’s revenue—there is always a risk of high concentration.
• The single manufacturing plant in Rajkot that produces the goods exposes the company to operational risks.
• The long working capital cycle (308 days) is putting a lot of pressure on the company’s cash flows.
• The heavy dependence on suppliers—90% of raw materials come from only 10 vendors.

Peer Comparison

At the upper price band, Anlon’s P/E of 14.3x looks attractive relative to its listed peers.

By buying Anlon Healthcare, investors can enter a market that is growing very fast and the asking price is quite reasonable. The positive aspects are made up by profit, margin increase, and low debt. However, the company’s risks being the small scale, the dependence on major customers and the instability of sales.

Retail enthusiasm is evidenced by almost a 9x subscription, but institutional hesitancy and an unchanged GMP indicate a cautious outlook for listing. Long-term investors with a high-risk profile may find it attractive, while conservative ones may prefer to wait for the final subscription data or the listing performance.

FAQ’s

READ MORE ON

Read the full article here: Anlon Healthcare IPO Day 1 — For more updates, visit Wittiya – Top Business News, Stock Market Insights & Financial Updates (Wittiya).